MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective

Annual Review of Pharmacology and Toxicology

Volumn 56, Issue , 2016, Pages 361-383

  Liu, Jiabei ^a   Clough, Shannon J ^a   Hutchinson, Anthony J ^a   Adamah Biassi, Ekue B ^a   Popovska Gorevski, Marina ^a   Dubocovich, Margarita L ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Cancer; Circadian rhythm disorders; Depression; Drugs of abuse; Neuroprotection; Sleep disorders

Indexed keywords

AGOMELATINE; COCAINE; ESTROGEN RECEPTOR ALPHA; FLUOXETINE; G PROTEIN COUPLED RECEPTOR; K 185; LUZINDOLE; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MELATONIN RECEPTOR AGONIST; METHAMPHETAMINE; MORPHINE; N BUTANOYL 2 (2 METHOXY 6H ISOINDOL[2,1 A]INDOL 11 YL)ETHANAMINE; PAROXETINE; PARTIAL AGONIST; PHOSPHOLIPASE C; PROSTATE SPECIFIC ANTIGEN; RAMELTEON; REACTIVE OXYGEN METABOLITE; S 26131; SEROTONIN 2C RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SUPEROXIDE DISMUTASE; TAMOXIFEN; TASIMELTEON; TRICYCLIC ANTIDEPRESSANT AGENT; UCM 765; UNCLASSIFIED DRUG; UNINDEXED DRUG; LIGAND;

ALZHEIMER DISEASE; ANTIDEPRESSANT ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; BINDING AFFINITY; BRAIN ISCHEMIA; BREAST CANCER; CIRCADIAN RHYTHM SLEEP DISORDER; COCAINE DEPENDENCE; DRUG ABUSE; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; HUNTINGTON CHOREA; INSOMNIA; LEARNING; MAJOR DEPRESSION; MEMORY; METHAMPHETAMINE DEPENDENCE; MOOD DISORDER; MORPHINE ADDICTION; NEOPLASM; NEUROPROTECTION; NONHUMAN; NONREM SLEEP; PRIORITY JOURNAL; PROSTATE CANCER; REM SLEEP; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CIRCADIAN RHYTHM; METABOLISM; NEOPLASMS; PHYSIOLOGY; SLEEP WAKE DISORDERS;

ANIMALS; CIRCADIAN RHYTHM; HUMANS; LIGANDS; MELATONIN; NEOPLASMS; RECEPTOR, MELATONIN, MT1; RECEPTOR, MELATONIN, MT2; SLEEP WAKE DISORDERS;

EID: 84954107329     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010814-124742     Document Type: Review

References (151)

1. Reiter RJ. 1991. Melatonin: The chemical expression of darkness. Mol. Cell Endocrinol. 79:C153-58
2. Tosini G, Menaker M. 1996. Circadian rhythms in cultured mammalian retina. Science 272:419-21
3. Dubocovich ML, Delagrange P, Krause DN, Sugden D, Cardinali DP, Olcese J. 2010. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol. Rev. 62:343-80
4. FoulkesNS, Cassone-Corsi P, Borjigin J, Snyder SH. 1997. Rhythmic transcription: The molecular basis of circadian melatonin synthesis. Trends Neurosci. 20:487-92
5. Reppert SM,Weaver DR, Godson C. 1996. Melatonin receptors step into the light: cloning and classification of subtypes. Trends Pharmacol. Sci. 17:100-2
6. Dubocovich ML,MasanaMI, Iacob S, Sauri DM. 1997. Melatonin receptor antagonists that differentiate between the human Mel1a andMel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retinaML1 presynaptic heteroreceptor. Naunyn-Schmiedeberg's Arch. Pharmacol. 355:365-75
7. Audinot V, Mailliet F, Lahaye-Brasseur C, Bonnaud A, Le Gall A, et al. 2003. New selective ligands of human cloned melatonin MT1 andMT2 receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 367:553-61
8. Slaugenhaupt SA, Roca AL, Liebert CB, Altherr MR, Gusella JF, Reppert SM. 1995. Mapping of the gene for the Mel1a-melatonin receptor to human chromosome 4 (MTNR1A) and mouse chromosome 8 (Mtnr1a). Genomics 27:355-57
9. Liu C, Weaver DR, Jin X, Shearman LP, Pieschl RL, et al. 1997. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron 19:91-102
10. Al-Ghoul WM, HermanMD, Dubocovich ML. 1998. Melatonin receptor subtype expression in human cerebellum. NeuroReport 9:4063-68
11. Weaver DR, Rivkees SA, Reppert SM. 1989. Localization and characterization of melatonin receptors in rodent brain by in vitro autoradiography. J. Neurosci. 9:2581-90
12. Mazzucchelli C, Pannacci M, Nonno R, Lucini V, Fraschini F, Stankov BM. 1996. The melatonin receptor in the human brain: cloning experiments and distribution studies. Mol. Brain Res. 39:117-26
13. Adamah-Biassi EB, Zhang Y, Jung H, Vissapragada S,Miller RJ, Dubocovich ML. 2014. Distribution of MT1 melatonin receptor promoter-driven RFP expression in the brains of BAC C3H/HeN transgenic mice. J. Histochem. Cytochem. 62:70-84
14. Jin X, von Gall C, Pieschl RL, Gribkoff VK, Stehle JH, et al. 2003. Targeted disruption of the mouse Mel1b melatonin receptor. Mol. Cell. Biol. 23:1054-60
15. Dubocovich ML. 1988. Luzindole (N-0774): A novel melatonin receptor antagonist. J. Pharmacol. Exp. Ther. 246:902-10
16. Dubocovich ML. 1993. Melatonin receptor agonists and antagonists. In Trends in Drug Research, ed. V Claassen, pp. 285-91. Amsterdam: Elsevier
17. Dubocovich ML, Yun K, Al-Ghoul WM, Benloucif S, Masana MI. 1998. Selective MT2 melatonin receptor antagonists blockmelatonin-mediated phase advances of circadian rhythms. FASEB J. 12:1211-20
18. Dubocovich ML, Masana M. 1998. The efficacy of melatonin receptor analogues is dependent on the level of human melatonin receptor subtype expression. In Biological Clocks, Mechanisms and Applications, ed. Y Touitou, pp. 289-93. Amsterdam: Elsevier
19. Browning C, Beresford I, Fraser N, Giles H. 2000. Pharmacological characterization of human recombinant melatonin mt1 and MT2 receptors. Br. J. Pharmacol. 129:877-86
20. Sugden D, Yeh LK, Teh MT. 1999. Design of subtype selective melatonin receptor agonists and antagonists. Reprod. Nutr. Dev. 39:335-44
21. Baba K, Benleulmi-Chaachoua A, Journe AS, Kamal M, Guillaume JL, et al. 2013. Heteromeric MT1/MT2 melatonin receptors modulate photoreceptor function. Sci. Signal. 6:ra89
22. Rivara S, Pala D, Lodola A, Mor M, Lucini V, et al. 2012. MT1-selective melatonin receptor ligands: synthesis, pharmacological evaluation, and molecular dynamics investigation of N-{[(3-OSubstituted) anilino]alkyl}amides. ChemMedChem 7:1954-64
23. Descamps-François C, Yous S, Chavatte P, Audinot V, Bonnaud A, et al. 2003. Design and synthesis of naphthalenic dimers as selective MT1 melatoninergic ligands. J. Med. Chem. 46:1127-29
24. Kenakin TP. 2014. Orthosteric drug antagonism. In A Pharmacology Primer: Techniques for More Effective and Strategic Drug Discovery, ed. TP Kenakin, pp. 119-53. New York: Academic
25. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, et al. 2007. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. 320:1-13
26. Audinot V, Bonnaud A, Grandcolas L, RodriguezM, Nagel N, et al. 2008. Molecular cloning and pharmacological characterization of rat melatoninMT1 andMT2 receptors. Biochem. Pharmacol. 75:2007-19
27. Cogé F, Guenin SP, Fery I, Migaud M, Devavry S, et al. 2009. The end of a myth: cloning and characterization of the ovine melatonin MT2 receptor. Brit. J. Pharmacol. 158:1248-62
28. Mailliet F, Audinot V, Malpaux B, Bonnaud A, Delagrange P, et al. 2004. Molecular pharmacology of the ovine melatonin receptor: comparison with recombinant human MT1 and MT2 receptors. Biochem. Pharmacol. 67:667-77
29. Doolen S, Krause DN, Dubocovich ML, Duckles SP. 1998. Melatonin mediates two distinct responses in vascular smooth muscle. Eur. J. Pharmacol. 345:67-69
30. Ochoa-Sanchez R, Comai S, Lacoste B, Bambico FR, Dominguez-Lopez S, et al. 2011. Promotion of non-rapid eye movement sleep and activation of reticular thalamic neurons by a novel MT2 melatonin receptor ligand. J. Neurosci. 31:18439-52
31. Wan Q, Man H-Y, Liu F, Braunton J, Niznik HB, et al. 1999. Differential modulation of GABAA receptor function by Mel1a and Mel1b receptors. Nat. Neurosci. 2:401-3
32. Ayoub MA, Levoye A, Delagrange P, Jockers R. 2004. Preferential formation of MT1/MT2 melatonin receptor heterodimers with distinct ligand interaction properties compared withMT2 homodimers. Mol. Pharmacol. 66:312-21
33. Gerdin MJ, Masana MI, Dubocovich ML. 2004. Melatonin-mediated regulation of human MT1 melatonin receptors expressed in mammalian cells. Biochem. Pharmacol. 67:2023-30
34. Gerdin MJ, Masana MI, Rivera-Berm údez MA, Hudson RL, Earnest DJ, et al. 2004. Melatonin desensitizes endogenous MT2 melatonin receptors in the rat suprachiasmatic nucleus: relevance for defining the periods of sensitivity of the mammalian circadian clock to melatonin. FASEB J. 18:1646-56
35. Kokkola T, Vaittinen M, Laitinen JT. 2007. Inverse agonist exposure enhances ligand binding and G protein activation of the human MT1 melatonin receptor, but leads to receptor down-regulation. J. Pineal Res. 43:255-62
36. Kamal M, Gbahou F, Guillaume JL, Daulat AM, Benleulmi-Chaachoua A, et al. 2015. Convergence of melatonin and serotonin (5-HT) signaling at MT2/5-HT2C receptor heteromers. J. Biol. Chem. 290:11537-46
37. de BodinatC,Guardiola-Lemaitre B, Mocäer E, Renard P,MuñozC,Millan MJ. 2010. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat. Rev. Drug Discov. 9:628-42
38. Paulis L, Simko F, Laudon M. 2012. Cardiovascular effects of melatonin receptor agonists. Expert Opin. Investig. Drugs 21:1661-78
39. Mini LJ,Wang-Weigand S, Zhang J. 2007. Self-reported efficacy and tolerability of ramelteon 8 mg in older adults experiencing severe sleep-onset difficulty. Am. J. Geriatr. Pharmacother. 5:177-84
40. Rajaratnam SMW, Polymeropoulos MH, Fisher DM, Roth T, Scott C, et al. 2009. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet 373:482-91
41. Lavedan C, Forsberg M, Gentile AJ. 2015. Tasimelteon: A selective and unique receptor binding profile. Neuropharmacology 91:142-47
42. Kato K, Hirai K, Nishiyama K, Uchikawa O, Fukatsu K, et al. 2005. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 48:301-10
43. Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, et al. 2003. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2c receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J. Pharmacol. Exp. Ther. 306:954-64
44. Ying S-W, Rusak B, Delagrange P, Mocäer E, Renard P, Guardiola-Lematre B. 1996. Melatonin analogues as agonists and antagonists in the circadian system and other brain areas. Eur. J. Pharmacol. 296:33-42
45. Boutin JA, Audinot V, Ferry G, Delagrange P. 2005. Molecular tools to study melatonin pathways and actions. Trends Pharmacol. Sci. 26:412-19
46. Nishiyama K, Nishikawa H, Kato K, Miyamoto M, Tsukamoto T, Hirai K. 2014. Pharmacological characterization of M-II, the major human metabolite of ramelteon. Pharmacology 93:197-201
47. Arendt J, Skene DJ. 2005. Melatonin as a chronobiotic. Sleep Med. Rev. 9:25-39
48. Cajochen C, Kräuchi K, von Arx MA, Möri D, Graw P, Wirz-Justice A. 1996. Daytime melatonin administration enhances sleepiness and theta/alpha activity in the waking EEG. Neurosci. Lett. 207:209-13
49. Zhdanova IV. 2005. Melatonin as a hypnotic: pro. Sleep Med. Rev. 9:51-65
50. Lewy AJ, Ahmed S, Jackson JML, Sack RL. 1992. Melatonin shifts human circadian-rhythms according to a phase response curve. Chronobiol. Int. 9:380-92
51. Burgess HJ, Revell VL, Molina TA, Eastman CI. 2010. Human phase response curves to three days of daily melatonin: 0. 5 mg versus 3. 0 mg. J. Clin. Endocr. Metab. 95:3325-31
52. Lewy AJ, Emens JS, Lefler BJ, Yuhas K, Jackman AR. 2005. Melatonin entrains free-running blind people according to a physiological dose-response curve. Chronobiol. Int. 22:1093-106
53. Lewy AJ, Bauer VK, Cutler NL, Sack RL. 1998. Melatonin treatment of winter depression: A pilot study. Psychiat. Res. 77:57-61
54. Roth T, Roehrs T. 2003. Insomnia: epidemiology, characteristics, and consequences. Clin. Cornerstone 5:5-15
55. Roth T. 2007. Insomnia: definition, prevalence, etiology, and consequences. J. Clin. Sleep Med. 3:S7-10
56. Laudon M, Frydman-Marom A. 2014. Therapeutic effects of melatonin receptor agonists on sleep and comorbid disorders. Int. J. Mol. Sci. 15:15924-50
57. Zhu L, Zee PC. 2012. Circadian rhythm sleep disorders. Neurol. Clin. 30:1167-91
58. Mundey K, Benloucif S, Harsanyi K, Dubocovich ML, Zee PC. 2005. Phase-dependent treatment of delayed sleep phase syndrome with melatonin. Sleep 28:1271-78
59. Hunt AE, Al-Ghoul WM, Gillette MU, Dubocovich ML. 2001. Activation of MT2 melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock. Am. J. Physiol. Cell Physiol. 280:C110-18
60. Dubocovich ML. 2007. Melatonin receptors: role on sleep and circadian rhythm regulation. Sleep Med. 8(Suppl. 3):34-42
61. Benloucif S, Dubocovich ML. 1996. Melatonin and light induce phase shifts of circadian activity rhythms in the C3H/HeN mouse. J. Biol. Rhythms 11:113-25
62. Rawashdeh O, Hudson RL, Stepien I, Dubocovich ML. 2011. Circadian periods of sensitivity for ramelteon on the onset of running-wheel activity and the peak of suprachiasmatic nucleus neuronal firing rhythms in C3H/HeN mice. Chronobiol. Int. 28:31-38
63. Dubocovich M, Hudson RL, Smith MR. 2007. Use ofmice with genetic deletion ofMT1 and/orMT2 receptors to unravel the receptor type mediating phase shift of circadian rhythms by ramelteon. Presented at Annu. Conf. Am. Coll. Neuropsychopharmacol. (ACNP) Session II 177, Dec. 9-13, Boca Raton, FL
64. Dubocovich ML, Hudson RL, Sumaya IC, Masana MI, Manna E. 2005. Effect of MT1 melatonin receptor deletion on melatonin-mediated phase shift of circadian rhythms in the C57BL/6 mouse. J. Pineal Res. 39:113-20
65. Garfinkel D, Laudon M, Nof D, Zisapel N. 1995. Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet 346:541-44
66. Leger D, Laudon M, Zisapel N. 2004. Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy. Am. J. Med. 116:91-95
67. De Leersnyder H, ZisapelN, Laudon M. 2011. Prolonged-releasemelatonin for children with neurodevelopmental disorders. Pediatr. Neurol 45:23-26
68. Roth T, NirT,Zisapel N. 2015. Prolonged release melatonin for improving sleep in totally blind subjects: A pilot placebo-controlled multicenter trial. Nat. Sci. Sleep 7:13-23
69. Miyamoto M, Nishikawa H, Doken Y, Hirai K, Uchikawa O, Ohkawa S. 2004. The sleep-promoting action of ramelteon (TAK-375) in freely moving cats. Sleep 27:1319-25
70. Yukuhiro N, Kimura H, NishikawaH,Ohkawa S, Yoshikubo S, Miyamoto M. 2004. Effects of ramelteon (TAK-375) on nocturnal sleep in freely moving monkeys. Brain Res. 1027:59-66
71. Roth T, Stubbs C, Walsh JK. 2005. Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep 28:303-7
72. Richardson GS, Zee PC,Wang-Weigand S, Rodriguez L, Peng X. 2008. Circadian phase-shifting effects of repeated ramelteon administration in healthy adults. J. Clin. Sleep Med. 4:456-61
73. Hirai K, Kita M, Ohta H, Nishikawa H, Fujiwara Y, et al. 2005. Ramelteon (TAK-375) accelerates reentrainment of circadian rhythm after a phase advance of the light-dark cycle in rats. J. Biol. Rhythms 20:27-37
74. Stahl SM. 2014. Mechanism of action of tasimelteon in non-24 sleep-wake syndrome: treatment for a circadian rhythm disorder in blind patients. CNS Spectrums 19:475-78
75. Mattson RJ, Catt JD, Keavy D, Sloan CP, Epperson J, et al. 2003. Indanyl piperazines as melatonergic MT2 selective agents. Bioorg. Med. Chem. Lett. 13:1199-202
76. Fisher SP, SugdenD. 2009. Sleep-promoting action of IIK7, a selectiveMT2 melatonin receptor agonist in the rat. Neurosci. Lett. 457:93-96
77. Comai S,Ochoa-Sanchez R, Gobbi G. 2013. Sleep-wake characterization of doubleMT1/MT2 receptor knockout mice and comparison withMT1 andMT2 receptor knockout mice. Behav. Brain Res. 243:231-38
78. Murray CJL, Lopez AD. 1997. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349:1498-504
79. Williams JW, Mulrow CD, Chiquette E, Noel PH, Aguilar C, Cornell J. 2000. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann. Intern. Med. 132:743-56
80. Anderson IM, Tomenson BM. 1995. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: A metaanalysis. Br. Med. J. 310:1433-38
81. Micale V, Arezzi A, Rampello L, Drago F. 2006. Melatonin affects the immobility time of rats in the forced swim test: The role of serotonin neurotransmission. Eur. Neuropsychopharm. 16:538-45
82. Overstreet DH, Pucilowski O, Retton MC, Delagrange P, Guardiola-Lemaitre B. 1998. Effects of melatonin receptor ligands on swim test immobility. NeuroReport 9:249-53
83. Liu JB, Somera-Molina KC, Hudson RL,Dubocovich ML. 2013. Melatonin potentiates running wheelinduced neurogenesis in the dentate gyrus of adult C3H/HeN mice hippocampus. J. Pineal. Res. 54:222-31
84. Ramrez-RodriguezG,Ortiz-Ĺopez L,Dominguez-Alonso A, Bentez-King GA, Kempermann G. 2011. Chronic treatment with melatonin stimulates dendrite maturation and complexity in adult hippocampal neurogenesis of mice. J. Pineal Res. 50:29-37
85. Ramrez-Rodriguez G, Klempin F, Babu H, Bentez-King G, Kempermann G. 2009. Melatonin modulates cell survival of new neurons in the hippocampus of adult mice. Neuropsychopharmacology 34:2180-91
86. Weil ZM, Hotchkiss AK, Gatien ML, Pieke-Dahl S, Nelson RJ. 2006. Melatonin receptor (MT1) knockout mice display depression-like behaviors and deficits in sensorimotor gating. Brain Res. Bull. 68:425-29
87. Adamah-Biassi EB, Hudson RL, Dubocovich ML. 2014. Genetic deletion of MT1 melatonin receptors alters spontaneous behavioral rhythms in male and female C57BL/6 mice. Hormones Behav. 66:619-27
88. Wu Y-H, Ursinus J, Zhou J-N, Scheer FAJL, Bao A-M, et al. 2013. Alterations of melatonin receptors MT1 andMT2 in the hypothalamic suprachiasmatic nucleus during depression. J. Affect. Disord. 148:357-67
89. Hansen MV,Danielsen AK,Hageman I, Rosenberg J,Gogenur I. 2014. The therapeutic or prophylactic effect of exogenous melatonin against depression and depressive symptoms: A systematic review andmetaanalysis. Eur. Neuropsychopharm. 24:1719-28
90. Hickie IB, Rogers NL. 2011. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet 378:621-31
91. Bertaina-Anglade V, Drieu la Rochelle C, Boyer P-A, Mocäer E. 2006. Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model. Behav. Pharmacol. 17:703-13
92. Banasr M, Soumier A,HeryM,Mocäer E, Daszuta A. 2006. Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis. Biol. Psychiatry 59:1087-96
93. Soumier A, Banasr M, Lortet S, Masmejean F, Bernard N, et al. 2009. Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus. Neuropsychopharmacology 34:2390-403
94. Schmelting B, Corbach-Soehle S,Kohlhause S, SchlumbohmC, Fluegge G, Fuchs E. 2014. Agomelatine in the tree shrew model of depression: effects on stress-induced nocturnal hyperthermia and hormonal status. Eur. Neuropsychopharm. 24:437-47
95. Dubocovich ML,Mogilnicka E, Areso PM. 1990. Antidepressant-like activity of the melatonin receptor antagonist, luzindole (N-0774), in the mouse behavioral despair test. Eur. J. Pharmacol. 182:313-25
96. Sumaya IC,MasanaMI, Dubocovich ML. 2005. The antidepressant-like effect of the melatonin receptor ligand luzindole in mice during forced swimming requires expression of MT2 but not MT1 melatonin receptors. J. Pineal Res. 39:170-77
97. DubocovichML,Sumaya IC, ZelivyanskayaML,SotoC, Stepien I. 2006. Antidepressant-like effect in the swimming test and increased cell proliferation/survival in hippocampus of adult C3H/HeN mice chronically treated with the melatonin (MLT) receptor ligand luzindole. Neuropsychopharmacology 31:S172
98. Souetre E, Salvati E, Belugou JL, Pringuey D, Candito M, et al. 1989. Circadian-rhythms in depression and recovery: evidence for blunted amplitude as the main chronobiological abnormality. Psychiat. Res. 28:263-78
99. Kräuchi K, Cajochen C, Möri D, Graw P,Wirz-Justice A. 1997. Early evening melatonin and S-20098 advance circadian phase and nocturnal regulation of core body temperature. Am. J. Physiol. 272:R1178-88
100. Leproult R, Van Onderbergen A, L'Hermite-Balériaux M, Van Cauter E, Copinschi G. 2005. Phaseshifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin. Endocrinol. 63:298-304
101. Lemoine P, Guilleminault C, Alvarez E. 2007. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J. Clin. Psychiatry 68:1723-32
102. Duman RS, Monteggia LM. 2006. A neurotrophic model for stress-related mood disorders. Biol. Psychiatry 59:1116-27
103. Kempermann G, Wiskott L, Gage FH. 2004. Functional significance of adult neurogenesis. Curr. Opin. Neurobiol. 14:186-91
104. Racagni G, Riva MA, Molteni R, Musazzi L, Calabrese F, et al. 2011. Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors. World J. Biol. Psychiatry 12:574-87
105. ThiesW, Bleiler L. 2012. 2012 Alzheimer's disease facts and figures. Alzheimer's Dement. 8:131-68
106. Savaskan E, Ayoub MA, Ravid R, Angeloni D, Fraschini F, et al. 2005. Reduced hippocampal MT2 melatonin receptor expression in Alzheimer's disease. J. Pineal Res. 38:10-16
107. Savaskan E, Olivieri G, Meier F, Brydon L, Jockers R, et al. 2002. Increased melatonin 1a-receptor immunoreactivity in the hippocampus of Alzheimer's disease patients. J. Pineal Res. 32:59-62
108. Cooke SF, Bliss TVP. 2006. Plasticity in the human central nervous system. Brain 129:1659-73
109. Bliss TVP, Collingridge GL. 1993. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361:31-39
110. Wang LM, Suthana NA, ChaudhuryD,Weaver DR, Colwell CS. 2005. Melatonin inhibits hippocampal long-term potentiation. Eur. J. Neurosci. 22:2231-37
111. Larson J, Jessen RE, Uz T, Arslan AD, Kurtuncu M, et al. 2006. Impaired hippocampal long-term potentiation in melatonin MT2 receptor-deficient mice. Neurosci. Lett. 393:23-26
112. Rawashdeh O, de Borsetti NH, Roman G, Cahill GM. 2007. Melatonin suppresses nighttime memory formation in zebrafish. Science 318:1144-46
113. O'Neal-Moffitt G, Pilli J, Kumar SS, Olcese J. 2014. Genetic deletion ofMT1/MT2 melatonin receptors enhances murine cognitive and motor performance. Neuroscience 277:506-21
114. Gorfine T, Zisapel N. 2007. Melatonin and the human hippocampus, a time dependent interplay. J. Pineal Res. 43:80-86
115. Tan DX, Manchester LC, Sainz RM, Mayo JC, Leon J, Reiter RJ. 2005. Physiological ischemia/reperfusion phenomena and their relation to endogenous melatonin production: A hypothesis. Endocrine 27:149-58
116. Galano A, Tan DX, Reiter RJ. 2013. On the free radical scavenging activities of melatonin's metabolites, AFMK and AMK. J. Pineal Res. 54:245-57
117. Parada E, Buendia I, León R, Negredo P, Romero A, et al. 2014. Neuroprotective effect of melatonin against ischemia is partially mediated by alpha-7 nicotinic receptormodulation andHO-1overexpression. J. Pineal Res. 56:204-12
118. Wang X, Sirianni A, Pei Z,Cormier K, SmithK, et al. 2011. ThemelatoninMT1 receptor axis modulates mutant huntingtin-mediated toxicity. J. Neurosci. 31:14496-507
119. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, et al. 2014. Heart disease and stroke statistics-2015 update: A report from the American Heart Association. Circulation 131:e29-322
120. Lee CH, Yoo K-Y, Choi JH, Park OK, Hwang IK, et al. 2010. Melatonin's protective action against ischemic neuronal damage is associated with up-regulation of the MT2 melatonin receptor. J. Neurosci. Res. 88:2630-40
121. ChernC-M, Liao J-F, Wang Y-H, Shen Y-C. 2012. Melatonin ameliorates neural function by promoting endogenous neurogenesis through theMT2 melatonin receptor in ischemic-stroke mice. Free Radic. Biol. Med. 52:1634-47
122. Subst. Abus. Ment. Health Serv. Adm. 2013. Results of the 2012 national survey on drug use and health: summary of national findings., NSDUH Series H-46, HHS Publ. No. (SMA) 13-4795, US Dep. Health Hum. Serv., Rockville, MD. http://www. samhsa. gov/data/sites/default/files/NSDUHresults2012/NSDUHresults2012. pdf
123. Natl. Inst. Drug Abus. 2007. Drugs, brains, and behavior: The science of addiction. Natl. Inst. Health Publ. No. 14-5605, Bethesda, MD. http://www. drugabuse. gov/sites/default/files/soa-2014. pdf
124. Hutchinson AJ, Hudson RL, Dubocovich ML. 2012. Genetic deletion of MT1 and MT2 melatonin receptors differentially abrogates the development and expression of methamphetamine-induced locomotor sensitization during the day and the night in C3H/HeN mice. J. Pineal Res. 53:399-409
125. Hutchinson AJ, Ma J, Liu J, Hudson RL, Dubocovich ML. 2014. Role of MT1 melatonin receptors in methamphetamine-induced locomotor sensitization in C57BL/6 mice. Psychopharmacology 231:257-67
126. Clough SJ, Hutchinson AJ, Hudson RL, Dubocovich ML. 2014. Genetic deletion of the MT1 or MT2 melatonin receptors abrogates methamphetamine-induced reward in C3H/HeN mice. Physiol. Behav. 132:79-86
127. Uz T, Javaid JI, Manev H. 2002. Circadian differences in behavioral sensitization to cocaine: putative role of arylalkylamine N-acetyltransferase. Life Sci. 70:3069-75
128. Kurtuncu M, Arslan AD, Akhisaroglu M, Manev H, Uz T. 2004. Involvement of the pineal gland in diurnal cocaine reward in mice. Eur. J. Pharmacol. 489:203-5
129. Robinson TE, Berridge KC. 2000. The psychology and neurobiology of addiction: An incentivesensitization view. Addiction 95(Suppl. 2):S91-117
130. Masana MI, Benloucif S, Dubocovich ML. 2000. Circadian rhythm ofmt1 melatonin receptor expression in the suprachiasmatic nucleus of the C3H/HeN mouse. J. Pineal Res. 28:185-92
131. Roseboom PH, Namboodiri MAA, Zimonjic DB, Popescu NC, Rodriguez IR, et al. 1998. Natural melatonin 'knockdown' in C57BL/6J mice: rare mechanism truncates serotonin N-acetyltransferase. Brain Res. Mol. Brain Res. 63:189-97
132. Han J, Xu Y, Yu C-X, Shen J,Wei Y-M. 2008. Melatonin reverses the expression of morphine-induced conditioned place preference through its receptors within central nervous system in mice. Eur. J. Pharmacol. 594:125-31
133. Witt-Enderby PA, RadioNM, Doctor JS,Davis VL. 2006. Therapeutic treatments potentially mediated by melatonin receptors: potential clinical uses in the prevention of osteoporosis, cancer and as an adjuvant therapy. J. Pineal Res. 41:297-305
134. Lissoni P, Barni S, Mandala M, Ardizzoia A, Paolorossi F, et al. 1999. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur. J. Cancer 35:1688-92
135. Lissoni P, Barni S, Meregalli S, Fossati V, Cazzaniga M, et al. 1995. Modulation of cancer endocrine therapy by melatonin: A Phase II study of tamoxifen plus melatonin in metastatic breast-cancer patients progressing under tamoxifen alone. Brit. J. Cancer 71:854-56
136. Jemal A, Thomas A, Murray T, Thun M. 2002. Cancer statistics, 2002. CA Cancer J. Clin. 52:23-47
137. Lissoni P, Ardizzoia A, Barni S, Paolorossi F, Tancini G, et al. 1995. A randomized study of tamoxifen alone versus tamoxifen plus melatonin in estrogen receptor-negative heavily pretreated metastatic breastcancer patients. Oncol. Rep. 2:871-73
138. Davis S, Mirick DK, Stevens RG. 2001. Night shift work, light at night, and risk of breast cancer. J. Natl. Cancer Inst. 93:1557-62
139. Shah PN, Mhatre MC, Kothari LS. 1984. Effect of melatonin on mammary carcinogenesis in intact and pinealectomized rats in varying photoperiods. Cancer Res. 44:3403-7
140. Blask DE, Brainard GC, Dauchy RT, Hanifin JP, Davidson LK, et al. 2005. Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. Cancer Res. 65:11174-84
141. Blask DE, Sauer LA, Dauchy RT, Holowachuk EW, RuhoffMS, Kopff HS. 1999. Melatonin inhibition of cancer growth in vivo involves suppression of tumor fatty acid metabolism via melatonin receptormediated signal transduction events. Cancer Res. 59:4693-701
142. Ram PT, Dai J, Yuan L, Dong C, Kiefer TL, et al. 2002. Involvement of the mt1 melatonin receptor in human breast cancer. Cancer Lett. 179:141-50
143. Lai L, Yuan L, Cheng Q, Dong CM,Mao LL, Hill SM. 2009. Alteration of theMT1 melatonin receptor gene and its expression in primary human breast tumors and breast cancer cell lines. Breast Cancer Res. Treat. 118:293-305
144. Rögelsperger O, Ekmekcioglu C, Jäger W, Klimpfinger M, Königsberg R, et al. 2009. Coexpression of the melatonin receptor 1 and nestin in human breast cancer specimens. J. Pineal Res. 46:422-32
145. Yuan L, Collins AR, Dai J, Dubocovich ML, Hill SM. 2002. MT1 melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. Mol. Cell Endocrinol. 192:147-56
146. Collins A, Yuan L, Kiefer TL, Cheng Q, Lai L, Hill SM. 2003. Overexpression of the MT1 melatonin receptor in MCF-7 human breast cancer cells inhibits mammary tumor formation in nude mice. Cancer Lett. 189:49-57
147. Xi SC, Tam PC, Brown GM, Pang SF, Shiu SYW. 2000. Potential involvement of mt1 receptor and attenuated sex steroid-induced calcium influx in the direct anti-proliferative action of melatonin on androgen-responsive LNCaP human prostate cancer cells. J. Pineal Res. 29:172-83
148. Xi SC, Siu SWF, Fong SW, Shiu SYW. 2001. Inhibition of androgen-sensitive LNCaP prostate cancer growth in vivo by melatonin: Association of antiproliferative action of the pineal hormone with mt1 receptor protein expression. Prostate 46:52-61
149. Shiu SYW, Law IC, Lau KW, Tam PC, Yip AWC, Ng WT. 2003. Melatonin slowed the early biochemical progression of hormone-refractory prostate cancer in a patient whose prostate tumor tissue expressed MT1 receptor subtype. J. Pineal Res. 35:177-82
150. Tam CW, Mo CW, Yao K-M, Shiu SYW. 2007. Signalingmechanisms of melatonin in antiproliferation of hormone-refractory 22Rv1 human prostate cancer cells: implications for prostate cancer chemoprevention. J. Pineal Res. 42:191-202
151. Clough SJ, Hutchinson AJ, Dubocovich ML. 2016. Melatonin receptors as modulators of methamphetamine mediated behaviors. In The Neuropathology of Drug Addictions and Substance Misuse, ed. V Preedy. New York: Academic. In press